List of Excipients in Branded Drug MEROPENEM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WG Critical Care LLC	MEROPENEM	meropenem	44567-402	SODIUM CARBONATE
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	SODIUM CARBONATE
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	SODIUM CHLORIDE
B Braun Medical Inc	MEROPENEM AND SODIUM CHLORIDE	meropenem and sodium chloride	0264-3183	WATER

Generic Drugs Containing MEROPENEM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	meropenem	0143-9431	SODIUM CARBONATE
Sandoz Inc	meropenem	0781-3000	SODIUM CARBONATE
Sandoz Inc	meropenem	0781-3098	SODIUM CARBONATE
Sagent Pharmaceuticals	meropenem	25021-161	SODIUM CARBONATE
WG Critical Care LLC	meropenem	44567-145	SODIUM CARBONATE
WG Critical Care LLC	meropenem	44567-400	SODIUM CARBONATE
Savior Lifetec Corporation	meropenem	44647-032	SODIUM CARBONATE

What are the Most Frequently-Used Excipients in MEROPENEM?

# Of NDCs	Excipient
23	SODIUM CARBONATE

Meropenem Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Meropenem is an established intravenous carbapenem with limited active-ingredient exclusivity and intense generic competition. Commercial value now depends on formulation performance, supply reliability, ready-to-use presentation, pediatric usability, and differentiated delivery systems rather than new meropenem composition-of-matter patents. The central formulation constraint is chemical instability in aqueous solution, which limits room-temperature shelf life and creates opportunities for improved premixes, dual-chamber systems, and hospital-ready presentations.

What is the current FDA status of meropenem?

Meropenem is FDA-approved as an intravenous antibacterial for serious infections caused by susceptible organisms, including complicated intra-abdominal infections, bacterial meningitis in pediatric patients, and other labeled indications depending on the product and jurisdiction.[1]

The reference product, Merrem I.V., is supplied as a sterile powder containing meropenem trihydrate equivalent to meropenem and anhydrous sodium carbonate. It is reconstituted before intravenous bolus injection or infusion.[1]

Attribute	Meropenem status
Active ingredient	Meropenem
Drug class	Carbapenem beta-lactam antibiotic
Primary route	Intravenous
Common hospital dose	500 mg or 1 g every eight hours, indication-dependent
Pediatric use	Established, including meningitis dosing
Reference product	Merrem I.V.
FDA pathway for generics	ANDA
Biosimilar pathway	Not applicable
Core formulation	Sterile lyophilized or dry powder containing meropenem trihydrate and sodium carbonate
Main formulation limitation	Instability after aqueous reconstitution
Current market structure	Multiple generic manufacturers and institutional suppliers

FDA-approved generic meropenem products are available in multiple vial strengths, generally including 500 mg and 1 g. Product availability varies by manufacturer, contract status, and shortage conditions. The FDA Orange Book remains the controlling source for current therapeutic-equivalence codes and listed patents or exclusivities.[2]

What excipients are used in meropenem injection?

The principal excipient in the reference formulation is anhydrous sodium carbonate. It is not an incidental bulking agent. Sodium carbonate helps establish an alkaline microenvironment that supports meropenem stability in the dry product and after reconstitution.

Why sodium carbonate is important

Meropenem contains a beta-lactam ring that is vulnerable to hydrolytic degradation in water. Its stability is affected by pH, temperature, concentration, ionic environment, light exposure, and contact with other injectable materials.

Sodium carbonate contributes to:

• pH control;
• chemical stability during manufacture and storage;
• acceptable dissolution behavior;
• reconstitution performance;
• compatibility with intravenous administration.

The amount of sodium carbonate must be controlled because excessive alkalinity can create compatibility and tolerability concerns. The excipient also affects osmolality, reconstitution pH, solution appearance, and the formulation's interaction with infusion fluids.

What excipients are generally absent?

Meropenem powder for injection typically does not require antimicrobial preservatives because it is supplied as a sterile single-dose product. It also does not require a conventional surfactant, oil phase, or complex stabilizer system.

The absence of multiple excipients creates a relatively simple abbreviated drug product but reduces the number of conventional formulation levers available to improve stability. Commercial differentiation therefore depends on process design, container closure, solid-state control, and presentation.

What formulation patents protect meropenem products?

The original meropenem composition-of-matter and pharmaceutical-development patents are historical assets. The commercial opportunity is not based on extending the original active-ingredient patent term. Meropenem has been marketed for decades, and generic intravenous products are approved in the United States and other major markets.

Current patent analysis should separate four categories:

Patent category	Commercial relevance
Original meropenem compound patents	Generally expired or commercially exhausted
Basic meropenem injectable formulations	Largely expired for the core product
Manufacturing and crystallization patents	Potentially relevant if still enforceable in a specific jurisdiction
Combination, device, or presentation patents	May support limited differentiation, especially with beta-lactamase inhibitors or ready-to-use systems

The principal risk is often regulatory and technical rather than patent-based. A company seeking to launch a new meropenem product must address sterile manufacturing, particulate control, reconstitution performance, extractables and leachables, container closure integrity, stability, and bioequivalence or equivalence requirements.

The Orange Book should be reviewed for the specific reference-listed product and current patent certifications before a launch decision.[2] Meropenem's mature generic status means a new formulation usually requires a clearly defined technical or commercial advantage to justify development costs.

When does meropenem lose exclusivity?

Meropenem's original market exclusivity and core patent protection have ended in the United States. The drug is available through ANDA-approved generic products, and the reference formulation no longer controls the market through meaningful brand exclusivity.

The relevant commercial timeline is therefore:

Period	Market event
1990s	Meropenem introduced as a hospital carbapenem
1996	U.S. approval of Merrem I.V.
Late 2000s onward	Broad generic development and market entry
Current market	Mature generic market with institutional purchasing pressure
Future opportunity	Reformulation, combination products, supply contracts, and differentiated delivery

No new pediatric, orphan, or biologic exclusivity framework is central to ordinary meropenem injection. A company cannot rely on a new meropenem formulation alone to recreate the commercial protection of an innovator launch.

How stable is meropenem after reconstitution?

Meropenem has limited stability after reconstitution, particularly at elevated temperatures. The approved product labeling provides different use periods depending on diluent, storage temperature, concentration, and administration conditions.[1]

Typical label-directed handling includes:

• preparation close to the time of administration;
• use of compatible infusion fluids;
• controlled storage after reconstitution;
• avoidance of prolonged exposure to room temperature;
• adherence to product-specific in-use periods.

Normal saline generally offers better practical stability than dextrose-containing solutions. Meropenem solutions can degrade more quickly in dextrose, and hospitals may have shorter permitted use periods for those preparations.[1]

Excipient and process variables that affect stability

A development program should evaluate:

1. Sodium carbonate level and buffer capacity.
2. Residual moisture in the powder.
3. Meropenem polymorph and hydrate state.
4. Headspace oxygen and moisture.
5. Vial stopper permeability.
6. Reconstitution time and undissolved particles.
7. Solution pH after dilution.
8. Temperature excursions during transport.
9. Compatibility with elastomeric infusion devices.
10. Light exposure during storage and administration.

The strongest formulation opportunity is usually not a new excipient in isolation. It is an integrated package combining a controlled solid state, low-moisture sterile process, optimized vial, and validated in-use stability.

What excipient strategies can improve meropenem products?

Optimized carbonate buffering

Sodium carbonate remains the most direct formulation lever. A developer can optimize its concentration, distribution, and manufacturing conditions to improve powder stability and reconstitution while limiting excessive alkalinity.

The patentability of this approach depends on claim specificity. Broad claims covering meropenem plus sodium carbonate are vulnerable because the combination is known. Narrow claims could focus on:

• a defined molar ratio;
• a specified pH range;
• a moisture threshold;
• a particular polymorphic form;
• a reconstitution profile;
• a stability result under defined conditions.

Alternative buffering systems

Alternative alkaline buffers may be technically feasible, but they face substantial development risk. Substitution must be evaluated for:

• chemical degradation;
• pH drift;
• osmolality;
• precipitation;
• infusion-site tolerability;
• container compatibility;
• regulatory precedent.

A new buffer is more commercially credible when it enables a measurable improvement, such as a longer room-temperature in-use period or a stable concentrated solution.

Bulking and cake-forming agents

Bulking agents such as mannitol may be considered in a lyophilized product, but they can change cake structure, residual moisture, reconstitution time, and vial fill weight. Their value is primarily manufacturing and presentation-related. They do not automatically solve meropenem's aqueous instability.

Antioxidant strategy

Oxidative degradation should be assessed, but antioxidants are not an obvious default addition. An antioxidant may create new regulatory and compatibility questions, especially for an injectable antibiotic with an established simple formulation. Oxygen control, low-moisture processing, and container selection may be more attractive than adding a reactive excipient.

Container closure and packaging

Packaging is a major commercial lever. Options include:

• low-permeability elastomeric stoppers;
• improved aluminum seals;
• moisture-barrier secondary packaging;
• nitrogen backfill;
• single-dose pharmacy-ready vials;
• dual-chamber bags or syringes;
• temperature-indicating labels for hospital logistics.

These approaches may create stronger practical differentiation than an excipient change because they address supply-chain and administration problems directly.

What commercial opportunities exist for meropenem formulations?

Ready-to-use premixed solutions

A ready-to-use meropenem infusion could reduce pharmacy preparation, nursing time, contamination risk, and medication errors. The primary barrier is solution stability. A commercially viable product would need a shelf life long enough for centralized manufacturing, distribution, hospital storage, and administration.

The highest-value formulation target is a room-temperature-stable premix. A refrigerated product could still have commercial value, but cold-chain requirements would reduce adoption and increase logistics costs.

Dual-chamber delivery systems

A dual-chamber bag can separate dry meropenem from the diluent until administration. This format directly addresses aqueous instability and may allow a longer commercial shelf life than a conventional premixed solution.

Potential advantages include:

• reduced pharmacy compounding;
• lower preparation error;
• faster administration;
• improved emergency-use readiness;
• lower exposure to contamination;
• compatibility with antimicrobial stewardship workflows.

The main challenges are device cost, seal integrity, activation reliability, extractables and leachables, and regulatory complexity.

Elastomeric and ambulatory infusion systems

Meropenem is increasingly relevant to outpatient parenteral antimicrobial therapy. An elastomeric pump or pharmacy-compounded ambulatory system could support hospital discharge and home infusion.

The technical issue is stability over the complete administration period. Product development must study meropenem concentration, pump material, temperature, flow rate, and storage time. This market is attractive where hospitals are shifting suitable patients from inpatient treatment to outpatient care.

Pediatric and neonatal presentations

Pediatric use creates a need for flexible dosing and low-waste presentations. Commercial opportunities include:

• lower-strength vials;
• ready-to-administer diluted products;
• pharmacy-friendly reconstitution systems;
• reduced overfill;
• dose-efficient packaging;
• compatibility with neonatal infusion equipment.

Any pediatric product must address preservative avoidance, dosing accuracy, low extractables, and small-volume administration.

Meropenem-vaborbactam combinations

Vabomere combines meropenem with vaborbactam, a beta-lactamase inhibitor, for specified resistant Gram-negative infections. The combination is a distinct commercial product from ordinary meropenem and has a separate patent and regulatory profile.[3]

This market offers greater differentiation than standalone meropenem but also introduces:

• combination-ratio constraints;
• separate stability requirements;
• higher clinical and regulatory costs;
• more complex patent analysis;
• narrower target populations;
• competition from ceftazidime-avibactam and cefiderocol.

A company should not assume that a meropenem excipient platform automatically transfers to meropenem-vaborbactam. The inhibitor may change pH sensitivity, degradation pathways, and allowable manufacturing conditions.

How does meropenem compare with competing carbapenems?

Product	Route	Formulation opportunity	Commercial position
Meropenem	IV	Premix, dual chamber, outpatient pump, pediatric delivery	Mature generic, high volume
Imipenem/cilastatin	IV	Combination stability and delivery systems	Mature generic, more complex active system
Ertapenem	IV/IM	Longer dosing interval, reconstitution and outpatient formats	Differentiated by once-daily dosing
Doripenem	IV	Limited opportunity in many markets	Smaller commercial footprint
Meropenem/vaborbactam	IV	Combination stability and resistance-focused delivery	Higher-value resistant-infection segment

Meropenem has an advantage in broad hospital familiarity, pediatric use, and procurement volume. Ertapenem has a dosing convenience advantage. Meropenem-vaborbactam has greater resistance-focused value but a narrower patient population and higher product complexity.

Which companies are challenging meropenem's market?

The ordinary meropenem market is challenged by generic manufacturers, contract manufacturers, hospital suppliers, and distributors rather than by a single branded competitor. Competition is based on:

• bid price;
• shortage resilience;
• vial availability;
• manufacturing capacity;
• quality history;
• supply continuity;
• pharmacy convenience;
• global registration coverage.

In the resistant-infection segment, meropenem-vaborbactam competes with other newer beta-lactam/beta-lactamase inhibitor products and reserve antibiotics. That market is more clinically differentiated but remains dependent on antimicrobial stewardship and hospital formulary restrictions.

What patent litigation and Paragraph IV risks affect meropenem?

Standalone meropenem is not primarily a current Paragraph IV opportunity against an active innovator patent estate. The basic product is genericized, and ordinary ANDA competition is established.

Paragraph IV risk becomes more relevant for:

• new meropenem-vaborbactam products;
• proprietary ready-to-use presentations;
• dual-chamber delivery systems;
• specific stability-enhanced formulations;
• device-enabled outpatient products;
• method-of-use claims for resistant infections.

A formulation patent is strongest when it claims a clinically useful result that is difficult to design around. Examples include a defined in-use stability period, a particular concentration and pH range, or a device configuration that prevents premature contact between meropenem and diluent.

A weak patent strategy would rely on merely adding a conventional excipient without demonstrating an unexpected stability or usability benefit.

What regulatory barriers apply to new meropenem formulations?

FDA development requirements depend on whether the product is an ordinary generic, a reformulated injection, a combination product, or a drug-device system.

Key regulatory issues include:

• sterile manufacturing validation;
• analytical characterization of degradation products;
• container closure integrity;
• particulate and sterility testing;
• extractables and leachables;
• dilution and infusion compatibility;
• stability under labeled storage conditions;
• human factors for dual-chamber systems;
• device performance;
• bioequivalence or therapeutic equivalence strategy;
• antimicrobial resistance and stewardship labeling.

A simple vial with the same active ingredient and excipient profile may fit an ANDA framework. A proprietary premix, device, or materially different formulation may require a more complex regulatory strategy and stronger clinical or pharmaceutical equivalence justification.

How strong is the patent estate for meropenem excipient innovations?

The original meropenem patent estate is commercially weak because the drug is mature and generic. New excipient and delivery patents can still have value, but their strength depends on technical specificity.

Innovation	Patent strength potential	Commercial value
Meropenem plus known sodium carbonate	Low	Low unless performance is unexpected
Defined moisture and polymorph control	Moderate	Moderate to high for manufacturing reliability
Stability-enhanced dry powder process	Moderate	High if it reduces degradation and waste
Room-temperature-stable premix	High if technically enabled	High
Dual-chamber meropenem bag	Moderate to high	High in hospital and emergency settings
Pediatric dose-efficient presentation	Moderate	Moderate
Novel meropenem-vaborbactam formulation	Moderate to high	High but narrower market
Generic packaging change alone	Low	Limited

Geographic protection should be assessed separately in the United States, European Union, Japan, China, India, and major hospital markets. Patent term, regulatory data protection, device rights, and enforcement standards differ by jurisdiction.

What revenue exposure does meropenem create?

Standalone meropenem is usually a volume business with low unit margins. Revenue depends on institutional contracts, government tenders, shortages, and manufacturing cost.

The most attractive commercial segments are not necessarily the largest by unit volume:

1. Ready-to-use products that reduce pharmacy labor.
2. Dual-chamber systems for emergency and inpatient use.
3. Outpatient infusion products.
4. Pediatric and neonatal presentations.
5. Supply-secure products for shortage-prone markets.
6. Meropenem-vaborbactam or other resistance-focused combinations.

A new product should be evaluated on total treatment economics rather than vial price alone. Reduced preparation time, lower wastage, fewer compounding steps, and improved availability can support premium pricing if the formulation is adopted by hospital pharmacy departments and group purchasing organizations.

Key Takeaways

• Meropenem is a mature generic intravenous antibiotic with no meaningful ordinary composition-of-matter exclusivity.
• Sodium carbonate is the central excipient in the established injectable formulation.
• Aqueous instability is the main technical constraint and the main formulation opportunity.
• The strongest commercial targets are ready-to-use premixes, dual-chamber systems, outpatient pumps, and pediatric presentations.
• New excipient patents need narrow, performance-based claims because broad meropenem-plus-buffer claims are vulnerable.
• Meropenem-vaborbactam offers higher differentiation but has greater regulatory, clinical, and patent complexity.
• Commercial success will depend more on stability, packaging, supply reliability, and hospital workflow than on adding a conventional excipient.

FAQs About Meropenem Excipient and Formulation Strategy

Can meropenem be formulated as an oral product?

No established oral meropenem product is marketed. Meropenem is administered parenterally because oral delivery would need to overcome permeability, degradation, and adequate systemic exposure challenges.

Is sodium bicarbonate a substitute for sodium carbonate in meropenem injection?

It may be investigated as an alternative alkaline excipient, but substitution is not automatic. The developer must demonstrate acceptable pH, stability, osmolality, compatibility, and injectable safety.

Can meropenem be supplied in a prefilled syringe?

A prefilled syringe is technically possible but requires validated chemical stability, syringe-material compatibility, sterilization or aseptic filling, extractables and leachables testing, and a clinically suitable administration period.

Does meropenem have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Meropenem is a chemically synthesized small-molecule drug and competes through generic drug pathways.

What is the best commercial formulation opportunity for meropenem?

A validated room-temperature-stable, ready-to-use or dual-chamber presentation has the strongest potential because it addresses meropenem's principal limitation while reducing hospital preparation burden.

References

1. U.S. Food and Drug Administration. (2024). Merrem I.V. (meropenem for injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Vabomere (meropenem and vaborbactam) prescribing information.
4. European Medicines Agency. (2018). Vaborem: European public assessment report.
5. United States Pharmacopeia. (2024). Meropenem monograph and general chapters for sterile pharmaceutical products.